国际肿瘤学杂志最新文献

{"title":"lncRNA and small cell lung cancer","authors":"Chao Ming, R. He, Yuan Sun, Linghan Tian, Guang-Li Zhao","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.011","url":null,"abstract":"The incidence and mortality of lung cancer rank first, and small cell lung cancer (SCLC) accounts for about 15% of lung cancer cases. In recent years, it has been found that long non-coding RNA (lncRNA) (TUG1, CCAT2, PVT1, HOTTIP and HOTAIR) plays a significant role in the development of SCLC. lncRNA can regulate the expression of related genes at the transcriptional, posttranscriptional and epigenetic levels, and it can infulence proliferation, invasion, metastasis and chemotherapy resistance of SCLC. \u0000 \u0000Key words: \u0000Small cell lung carcinoma; RNA, long noncoding","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"51 1","pages":"620-623"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85177614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advantages of carbon ion radiotherapy and its application in tumor therapy","authors":"Qian Li, Jin Zhou","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.008","url":null,"abstract":"Compared with proton and photon, heavy ion radiotherapy has unique physical and biological advantages, which enables it to kill tumor tissues to the greatest degree and protect surrounding normal tissues as much as possible. Carbon ion is recognized as the most suitable heavy ion for radiotherapy at present. Carbon ion radiotherapy in chordoma, head and neck cancer, non-small cell lung cancer, prostate cancer, cervical cancer and other malignant tumor treatment advantages have been preliminarily reflected. Therefore, understanding the characteristics of carbon ion radiotherapy and its application in tumor therapy will help clinicians make better clinical decisions in the future. \u0000 \u0000Key words: \u0000Heavy ion radiatherapy; Neoplasms; Carbon ion","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"43 1","pages":"609-612"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74212188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New progression in the therapy of blastic plasmacytoid dendritic cell neoplasms","authors":"Jingshi Yang, L. Zou","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.001","url":null,"abstract":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a kind of rare and highly invasive hematological malignancy. Because of its low incidence, there is still no consensus on its standard treatment. For young patients, high intensity chemotherapy combined with hematopoietic stem cell transplantation is often used. Elderly patients who cannot accept hematopoietic stem cell transplantation receive low intensity chemotherapy. In December 2018, tagraxofusp, a new targeted drug, was approved by the U. S. Food and Drug Administration specially for treatment-naive and previously-treated BPDCN patients (age≥2 years old). Some targeted drugs, such as venetoclax and daratumumab, have certain effects on the treatment of BPDCN. The efficacies of PD-1/PDL-1 inhibitors and anti CD123 chimeric antigen receptor T cell immunotherapy need further researches. \u0000 \u0000Key words: \u0000Hematological neoplasms; Therapy; Blastic plasmacytoid dendritic cell neoplasms","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"23 1","pages":"577-580"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72534695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of cystatin C and β2-microglobulin in the assessment of condition and short-term efficacy of multiple myeloma","authors":"Yunyu Zhang, Jing Peng, Zhigang Song, Xing-jing Li","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.10.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.10.004","url":null,"abstract":"Objective \u0000To explore the application value of serum cystatin C (Cys-C) and β2-microglobulin (β2-MG) in the diagnosis and short-term efficacy evaluation of multiple myeloma (MM). \u0000 \u0000 \u0000Methods \u0000A total of 450 patients with MM admitted to Anqing Hospital of Chinese People′s Liberation Army Navy and Jinhua Central Hospital of Zhejiang Province from October 2016 to October 2018 were selected as subjects (MM group), according to the Durie-Salmon staging criteria, including 150 patients in stage Ⅰ, Ⅱ and Ⅲ. A total of 150 healthy subjects were selected as the control group. The levels of Cys-C and β2-MG in the serum of the subjects were determined. The differences of Cys-C and β2-MG levels between the two groups and the MM patients with different Durie-Salmon stages were compared. The differences of Cys-C and β2-MG levels between the patients with different short-term efficacy were compared. The receiver operating characteristic (ROC) curve was used to analyze the value of the two indicators in the evaluation of MM efficacy, and the correlation between Cys-C and β2-GM was analyzed. Logistic regression analysis was used to analyze the multiple factors affecting the clinical efficacy of MM patients. \u0000 \u0000 \u0000Results \u0000The levels of Cys-C and β2-MG in the serum of the patients with MM were (2.11±0.78) mg/L and (6.07±3.08) g/L respectively, and those in the control group were (0.75±0.20) mg/L and (1.78±0.59) g/L, with significant differences (t=33.848, P<0.001; t=28.084, P<0.001). The Cys-C levels of Durie-Salmon stage Ⅰ, Ⅱ and Ⅲ patients were (0.99±0.21) mg/L, (1.36±0.17) mg/L and (3.07±1.02) mg/L respectively, and the difference was statistically significant (F=44.157, P<0.001). The β2-MG levels in the serum of patients with stage Ⅰ, Ⅱ and Ⅲ were (2.57±0.75) g/L, (4.66±1.43) g/L, (8.63±2.26) g/L respectively, and the difference was statistically significant (F=57.285, P<0.001). In all the patients, 338 patients were effective, accoun-ting for 75.11%, and 112 patients were ineffective, accounting for 24.89%. The levels of Cys-C and β2-MG in the serum of the effective MM patients were (1.28±0.23) mg/L and (2.82±0.78) g/L, and those of ineffective patients were (2.97±0.77) mg/L and (6.22±1.92) g/L, with statistically significant differences (t=35.874, P<0.001; t=26.633, P<0.001). The sensitivity of serum Cys-C for predicting short-term efficacy was 83.0%, the specificity was 76.6%, and those of serum β2-MG were 89.3% and 73.6%. The area under curve (AUC) of the serum Cys-C was 0.813 (95%CI: 0.764-0.862), and the AUC of serum β2-MG was 0.865 (95%CI: 0.825-0.906), with a statistically significant difference (Z=2.490, P=0.011). Spearman correlation analysis showed a positive correlation between serum Cys-C and β2-MG (r=0.539, P=0.041). Logistic regression analysis showed that both β2-MG (95%CI: 2.386-5.144, P<0.001) and Cys-C (95%CI: 2.367-9.702, P<0.001) were independent factors affecting the short-term efficacy of MM. Multivariate analysis showed that β2-MG (95%C","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"42 1","pages":"590-594"},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81279066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"癌症患者生命质量测定量表体系QLICP（V1.0）及其与欧洲QLQ和美国FACT量表的比较","authors":"杨铮 全鹏 罗家洪 孟琼 李高峰 寸英丽 万崇华","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.09.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.09.001","url":null,"abstract":"Objective \u0000To compare the differences and similarities among the system of quality of life instruments for cancer patients (QLICP) V1.0, the quality of life questionnaire (QLQ) from European Organization for Research and Treatment of Cancer (EORTC) and Functional Assessment of Cancer Therapy (FACT) from Center on Outcomes, Research and Education (CORE) of America. \u0000 \u0000 \u0000Methods \u0000Based on literatures and our measuring data from patients at hospitals, the constructs, characteristics and psychometrics of the systems above were analyzed and compared. Internal consistency reliability was assessed using Cronbach α coefficient for each domain, and test-retest reliability through calculating the Pearson correlation coefficient r between the first and second assessments as well as intra-class correlation (ICC). Construct validity was evaluated by Pearson correlation coefficient r (item-domains correlations) and factor analysis. The criterion-related validity was evaluated by correlating corresponding domains of two instruments. Responsiveness was assessed through comparing the mean difference between the pre-treatment and post-treatment with standardized response mean (SRM). \u0000 \u0000 \u0000Results \u0000The instruments of three systems were of different outstanding characteristics with all psychometrics meeting requirements. Measurements for 12 types of cancers showed that the internal consistency reliability Cronbach α coefficient for the overall scale of QLICP (V1.0) was 0.67-0.92, and for FACT was 0.79-0.98. The test-retest reliability (r or ICC) for the overall scale of QLICP (V1.0) was 0.61-0.99, and for FACT was 0.60-0.98. The SRM for the overall scale of QLICP (V1.0) was 0.25-1.28, and for FACT was 0.11-0.83. However, the QLICP was of better construct (clear hierarchical structure with items→facets→domains→overall) and Chinese culture. \u0000 \u0000 \u0000Conclusion \u0000The instruments of three systems can be used as the instruments to assess quality of life for patients with cancer with selections basing on different settings. \u0000 \u0000 \u0000Key words: \u0000Quality of life; Neoplasms; Behavior rating scale; Quality of life instruments for cancer patients","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"31 1","pages":"513-518"},"PeriodicalIF":0.0,"publicationDate":"2019-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75390095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LSD1、MGMT和Ki-67在高级别胶质瘤中的表达及对预后的影响","authors":"张洋 宿伟鹏 张宋安 刘攀 赵化荣 张千慧","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.09.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.09.002","url":null,"abstract":"Objective \u0000To investigate the expressions of histone lysine-specific demethylase 1 (LSD1), O6-methylguanine DNA methyltransferase (MGMT) and cell proliferation-associated antigen Ki-67 in high-grade glioma and their influences on prognosis. \u0000 \u0000 \u0000Methods \u0000Sixty-five cases of grade Ⅲ and Ⅳ glioma confirmed by pathology from January 2011 to June 2017 in the First Affiliated Hospital of Xinjiang Medical University were selected. Immunohistochemistry (SP method) was used to detect the expressions of LSD1, MGMT and Ki-67 in pathological specimens. The therapeutic effect was evaluated by long-term follow-up. The relationships between the three markers and pathological grade, progression-free survival (PFS) and overall survival (OS) were analyzed. \u0000 \u0000 \u0000Results \u0000The overall positive rates of LSD1, MGMT and Ki-67 in the 65 high-grade glioma specimens were 70.8% (46/65), 60.0% (39/65) and 100.0% (65/65), respectively. There were no significant differences in the expressions of LSD1 and MGMT in grade Ⅲ and Ⅳ glioma (χ2=1.588, P=0.208, χ2=0.013, P=0.908). Ki-67 expression (+ ), (+ + ), (+ + + ) in grade Ⅳ glioma were observed in 18, 19 and 11 cases, respectively. Ki-67 expression (+ ), (+ + ) in grade Ⅲ glioma were observed in 11, 5 cases, and 1 case was (+ + + ), and the difference in expression intensity between the two groups was statistically significant (Z=-2.083, P=0.037). Log-rank test showed that the positive expressions of LSD1, MGMT and Ki-67 were negatively correlated with the PFS of patients with high-grade glioma (χ2=12.217, P=0.007; χ2=4.446, P=0.035; χ2=12.536, P=0.002), also were negatively correlated with OS (χ2=11.708, P=0.008; χ2=6.637, P=0.010; χ2=11.807, P=0.003). Grade Ⅳ patients were more likely to have relapse progression than grade Ⅲ patients (χ2=6.573, P=0.010), and OS was shorter (χ2=3.974, P=0.046). Cox proportional hazards model analysis showed that the expressions of LSD1 (HR=1.361, 95%CI: 1.094-1.694, P=0.006; HR=1.406, 95%CI: 1.117-1.771, P=0.004) and Ki-67 (HR=1.703, 95%CI: 1.175-2.468, P=0.005; HR=1.778, 95%CI: 1.209-2.616, P=0.003) were the independent prognostic risk factors for PFS and OS of patients with high-grade glioma. Correlation analysis results showed that the expression of MGMT was positively correlated with the expression of LSD1 (r=0.406, P=0.001). \u0000 \u0000 \u0000Conclusion \u0000LSD1, MGMT and Ki-67 have higher positive expression rates in high-grade glioma. MGMT is a prognostic factor for high-grade glioma, and LSD1 and Ki-67 can be used as independent predictors of prognosis for high-grade gliomas. \u0000 \u0000 \u0000Key words: \u0000Glioma; O(6)-methylguanine-DNA methyltransferase; Ki-67 antigen; Prognosis; Lysine specific demethylase 1","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"10 1","pages":"519-525"},"PeriodicalIF":0.0,"publicationDate":"2019-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84337211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress of liquid biopsy in early diagnosis of lung cancer","authors":"Yuqiong Ding, G. Qiao","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.09.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.09.008","url":null,"abstract":"Liquid biopsy is a kind of emerging pathological detection technique, which has shown certain value in the diagnosis and treatment of lung cancer. Detections of circulating tumor cells, circulating tumor DNA, DNA methylation, microRNA, exosomes and tumor educated platelets in patients′ body fluids can be used for the early diagnosis and predicting the progress of lung cancer. At recent, the application of liquid biopsy still has some shortcomings. However, with the continuous development of detection technology, it may become an effective auxiliary or alternative method for imaging examination such as CT in the near future, and will provide a new direction for the diagnosis and treatment of lung cancer. \u0000 \u0000 \u0000Key words: \u0000Lung neoplasms; Diagnosis; Liquid biopsy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"27 1","pages":"548-552"},"PeriodicalIF":0.0,"publicationDate":"2019-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78369914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of radiogenomics in lung cancer","authors":"Jianlin Guo, Chuan Zhang, Hualong Yu","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.09.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.09.007","url":null,"abstract":"Radiogenomics aims at investigating the relationship between radiomics features and genomic features, which has certain practical value in the individualized molecular targeted therapy. Meanwhile, it is noninvasive, repeatable and inexpensive. In recent years, a large number of studies have shown that radiomics features have certain predictive values for the mutation status of driver genes of lung cancer. The application of radiogenomics is insufficient at present, but with its continuous improvement and development, it will play an increasingly important role in the precise therapy of lung cancer in the future. \u0000 \u0000 \u0000Key words: \u0000Lung neoplasms; Receptor, epidermal growth factor; Radiomics; Anaplastic lymphoma kinase","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"72 1","pages":"544-547"},"PeriodicalIF":0.0,"publicationDate":"2019-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89505288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNAs and diffuse large B cell lymphoma","authors":"Ye Sun, L. Sheng, G. Ouyang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.09.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.09.012","url":null,"abstract":"The molecular mechanism of diffuse large B cell lymphoma (DLBCL) has not been fully elucidated, and epigenetics plays an important role in its development. MicroRNAs (miRNAs) are important parts of epigenetics, which are involved in the occurrence and development of DLBCL. Relevant studies have found that miRNAs can not only be used as molecular diagnostic markers of DLBCL, but also be used to judge the prognosis and treatment effect of DLBCL. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, large B-cell, diffuse; MicroRNAs; B-lymphocytes; Diagnosis; Prognosis","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"94 1","pages":"566-569"},"PeriodicalIF":0.0,"publicationDate":"2019-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84213106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancement of the risk prediction of hepatocellular carcinoma in patients with chronic hepatitis B virus infection","authors":"Wen-jun Chen, Junjuan Wang, Jianni Qi, Chonghai Dong, C. Qin","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.09.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.09.010","url":null,"abstract":"It is of important significant to predict the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus infection in clinic. Various risks scoring systems can achieve better prediction effect by integrating a variety of risk factors, but they still need to be perfected. Recent researches have found that some genotypes and genetic variations are associated with the occurrence of HCC and they can indicate the tumorigenesis of HCC. Some known or newly discovered indicators such as WFA+ -M2BP can be used to predict the occurrence of HCC independently or jointly. With the development of research, more genes, indicators as well as newly built scoring system will be utilized to predict the occurrence of HCC in clinic. \u0000 \u0000 \u0000Key words: \u0000Hepatitis B virus; Infection; Carcinoma, hepatocellular; Risk assessment","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"11 1","pages":"558-561"},"PeriodicalIF":0.0,"publicationDate":"2019-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77754508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}